You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 20177705
Jul 20175407
Aug 201760018
Sep 2017154017
Oct 2017112020
Nov 2017114026
Dec 20176605
Jan 201882021
Feb 2018101015
Mar 20184003
Apr 20189608
May 20187407
Jun 20184604
Jul 20185601
Aug 20182403
Sep 20185008
Oct 20181207
Nov 201816018
Dec 201810010
Jan 20193014
Feb 2019101
Mar 20191106
Apr 2019604
May 2019908
Jun 20191204
Jul 2019804
Aug 2019805
Sep 20191105
Oct 2019204
Nov 20191008
Dec 2019006
Jan 2020601
Feb 2020401
Mar 20203405
Apr 202010010
May 2020600
Jun 20201602
Jul 20201203
Aug 2020804
Sep 20201202
Oct 2020404
Nov 2020201
Dec 20202203
Jan 2021604
Feb 20211901
Mar 20211207
Apr 2021200
May 2021607
Jun 2021003
Jul 2021307
Aug 20212013
Sep 2021104
Oct 202110021
Nov 20212014
Dec 2021709
Jan 2022303
Feb 2022503
Mar 2022804
Apr 2022200
May 2022905
Jun 20221603
Jul 20221102
Aug 2022801
Sep 2022708
Oct 20221204
Nov 2022605
Dec 2022902
Jan 20231006
Feb 2023301
Mar 2023801
Apr 20232011
May 2023102
Jun 2023101
Jul 2023104
Aug 2023208
Sep 20231003
Oct 2023401
Nov 2023001
Dec 20233400
Jan 2024504
Feb 2024401
Mar 20243016
Total17150498